Ardent Health Partners, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joanna Gajuk from Bank of America Securities downgraded the rating on the stock to a Sell and gave it a $14.60 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joanna Gajuk’s rating is based on anticipated financial challenges for Ardent Health Partners, Inc. due to recent legislative changes. The Reconciliation Bill has introduced cuts to Medicaid and ACA exchange funding, which are expected to reduce patient volume growth and increase bad debt for the company.
Ardent Health Partners is particularly vulnerable to these changes because of its significant reliance on Medicaid State Directed Payments. Additionally, the expiration of enhanced exchange subsidies is likely to further strain the company’s financial outlook, leading to a shift from previous growth trends to potential declines in earnings. These factors have prompted a downgrade in the company’s stock rating to Underperform and a reduction in the price objective.